

Gilead Could Move to Bundle Recent Idenix Patent Disputes, Likely to Hinge on Issues of Prior Art, Invalidity – Attorneys

January 5, 2014

ATTORNEYS

Landmon, Chad

Christine Livoti
BioPharm Insight

Axinn partner Chad Landmon was quoted in Christine Livoti's article, "Gilead Could Move to Bundle Recent Idenix Patent Disputes, Likely to Hinge on Issues of Prior Art, Invalidity – Attorneys," which was published January 9 in *BioPharm Insight*.

[Click here to view the article.](#)